Disease activity trajectories for early and established rheumatoid arthritis: Real-world data from a rheumatoid arthritis cohort

• Published in: PloS one Vol. 17; no. 9; p. e0274264
• Main Authors: Movahedi, Mohammad, Cesta, Angela, Li, Xiuying, Bombardier, Claire
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 07-09-2022; Public Library of Science (PLoS)
• Subjects: Arthritis; Arthritis, Rheumatoid - diagnosis; Arthritis, Rheumatoid - drug therapy; Autoimmune diseases; Biology and Life Sciences; Blood Sedimentation; Cardiovascular disease; Care and treatment; Cohort Studies; Comorbidity; Consent; Diagnosis; Erythrocyte sedimentation rate; Erythrocytes; Gastrointestinal cancer; Humans; Joint diseases; Medicine and Health Sciences; Patients; Physical Sciences; Remission; Remission (Medicine); Rheumatoid arthritis; Severity of Illness Index; Sociodemographics; Subgroups; Variables; Canada
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0274264

Disease activity status described at fixed time points does not accurately reflect disease course in chronic and relapsing diseases such as rheumatoid arthritis (RA). We described longitudinal disease activity trajectories in early and established RA.
Patients with available 28-Joint Disease Activity Score-erythrocyte sedimentation rate (DAS28-ESR) and Clinical Disease Activity Index (CDAI) over two years were included. Using latent growth curve modelling (LCGM), subgroups of patients following distinct patterns were identified.
1920 patients were included with 34.4% in early RA (< 2 years' disease duration). Three subgroups were identified using DAS28-ESR in early RA: 1) low disease activity to remission (LDA-REM: 19.1%); 2) moderate disease to remission (MD-REM: 54%); 3) high to moderate disease (HD-MD: 26.9%). The HD-MD group had a significantly higher number of comorbidities, biologic and steroid use and lower post-secondary education. Using CDAI, we identified seven subgroups with only 1.9% remission in early RA. In established RA, seven subgroups were identified using either DAS28-ESR or CDAI. Using DAS28-ESR 27.8% with HD showed improvement in disease status (14.2% HD-REM, 10.3% HD-LDA and 3.3% HD-MD) while using CDAI 17.9% showed improvement.
Disease course was different in early and established RA. Only 14.2% of established RA reached DAS28-ESR remission compared to 73.1% of early RA. Using CDAI only 1.9% of early RA and none of the established RA achieved remission, likely reflecting the impact of the patient global assessment on this score. Findings also illustrate the impact of sociodemographic characteristics and early treatment on disease course.